OncoMatch/Clinical Trials/NCT07052370
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Is NCT07052370 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments for hematologic malignancy.
Treatment: Thymoglobulin · Cyclophosphamide · Fludarabine · Thiotepa · Melphalan · Mesna · Filgrastim · Blinatumomab · CliniMACS — This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: \- To assess the safety and feasibility of early CD45RA-depleted DLI administration. The secondary objectives are * To assess the safety and feasibility of the addition of blinatumomab in the early post-transplant period in patients with CD19+ malignancy. * To measure and describe the pharmacokinetics of rabbit ATG in HCT recipients on this study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Received a prior allogeneic HCT at any time
Cannot have received: autologous hematopoietic cell transplant
Exception: within the previous 6 months
Received an autologous HCT within the previous 6 months
Lab requirements
Kidney function
creatinine clearance (crcl) or glomerular filtration rate (gfr) ≥ 50 ml/min/1.73m2
Liver function
bilirubin ≤ 3 times the upper limit of normal for age; alt or ast ≤ 5 times the upper limit of normal for age
Cardiac function
left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- St. Jude Children's Research Hospital · Memphis, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07052370 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic cell transplant, autologous hematopoietic cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify